文献速递淋巴瘤

原发性难治性大B细胞淋巴瘤的定义

Defining primary refractory large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

研究在单中心前瞻性MER队列(N=949)中分析原发难治性大B细胞淋巴瘤不同定义与生存的关系,并在独立多中心LEO队列(N=2755)中验证;结果发现原发进展性疾病(PPD)患者的总生存最差,2年OS率MER为15%、LEO为31%,低于EOT PR和早期复发组,据此提出原发难治性定义应为一线治疗期间或结束时疾病稳定或进展。

要点

  • PPD患者2年OS率MER为15%、LEO为31%,低于EOT PR和早期复发组。
  • EOT PR患者2年OS率MER为38%、LEO为50%;早期复发患者MER为44%、LEO为58%。
  • 作者提出原发难治性LBCL定义为一线治疗期间或结束时疾病稳定(SD)或进展(PD)。

核心结论

  • 在接受含蒽环类免疫化疗一线治疗的患者中,PPD是预后差的关键亚组。
  • 作者提出将原发难治性LBCL定义为一线治疗期间或结束时疾病稳定或进展。

研究设计与样本

  • 研究为单中心前瞻性队列(MER,N=949),并在独立多中心队列(LEO,N=2755)中验证。
  • 新诊断LBCL患者于2002年9月至2021年5月入组MER或LEO队列。

主要发现

  • PPD患者2年OS率MER为15%、LEO为31%,低于EOT PR(MER 38%、LEO 50%)和早期复发(MER 44%、LEO 58%)。
  • 研究比较了文献和临床实践中用于定义难治状态的不同复发时间及其与生存结局的关系。

关键数值与推荐

  • 原发难治性LBCL定义为一线免疫化疗期间或结束时无反应(SD)或PD(PPD)、治疗结束时PR(EOT PR),或达到CR后3至12个月内复发(早期复发)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered to have "primary refractory disease." However, different definitions of primary refractory disease are used in the literature and clinical practice. In this study, we examined variation in the time to relapse used to define refractory status and association with survival outcomes in patients with primary refractory LBCL in a single-center prospective cohort with validation in an independent multicenter cohort. Patients with newly diagnosed LBCL were enrolled in the Molecular Epidemiological Resource cohort (MER; N = 949) or the Lymphoma Epidemiology of Outcomes cohort (LEO; N = 2755) from September 2002 to May 2021. Primary refractory LBCL was defined as no response (stable disease [SD]) or progressive disease (PD) during, or by the end of, frontline (1L) IC (primary PD; PPD); partial response at end of treatment (EOT PR); or relapse within 3 to 12 months after achieving CR at EOT to 1L IC (early relapse). In the MER cohort, patients with PPD had inferior overall survival (OS; 2-year OS rate: 15% MER, 31% LEO) when compared with other subgroups considered in defining primary refractory disease, EOT PR (2-year OS rate: 38% MER, 50% LEO) and early relapse (2-year OS rate: 44% MER, 58% LEO). Among patients receiving 1L IC with curative intent, we identified that patients with PPD are the key subgroup with poor outcomes. We propose a definition of primary refractory LBCL as SD or PD during, or by the end of, 1L treatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bock AM, Mwangi R, Wang Y, et al. Defining primary refractory large B-cell lymphoma. Blood Adv. 2024. PMID: 38669353. doi:10.1182/bloodadvances.2024012760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。